Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

Abstract: The present invention relates to a method for the in vitro diagnosis of active tuberculosis, comprising a step of contacting lymphocytes of a patient suspected to have active tuberculosis with at least one protein of mycobacteria, said protein being an enzyme having a lipolytic activity, and a step of detecting the presence of specific activated lymphocytes.

Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

Abstract: A memory device includes at least one memory cell having a first transistor coupled between a first storage node and a first supply voltage; a second transistor coupled between a second storage node and the first supply voltage and a single resistance switching element. Control terminals of the first and second transistors are coupled to the second and first storage nodes respectively. The single resistive switching element is coupled in series with the first transistor and is programmable to have one of first and second resistances. The first storage node is coupled to a first access line via a third transistor connected to said first storage node, and the second storage node is coupled to a second access line via a fourth transistor connected to the second storage node.

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.

Abstract: Disclosed are specific antibodies against the protein Trio, their method of production, and their use in in vitro cancer prognostic method. Also described are the antigens enabling production of the antibodies.

Abstract: The invention relates to a static converter connected between an electrical voltage source and an electrical load, said converter including a main static conversion arm comprising an output electronic switching cell and a backup conversion arm having identical structures. The static converter includes a pair of fuses connected on either side of the main arm, and a switching circuit comprising a connection element connecting the backup arm to the connection points between the fuses and the input terminals of the main arm, such that, when a fault occurs on one of the switching cells forming the main arm, a stable conductive link is established between the two fuses, the main arm is isolated by the two fuses, and the backup arm is spontaneously connected to the output of the main arm via the conductive line and replaces the main arm.

Abstract: The invention relates to a polymer comprising at least one polymeric chain of a first type, the said chain comprising at least two blocks, the same or different, the said blocks comprising repeat units derived from the polymerisation of styrene monomers, the said units comprising at least one phenyl pendant group carrying at least one —SO3R group, R possibly being a hydrogen atom, an alkyl group or cationic counter-ion, the said two blocks being separated by a spacer group, the spacer group is a perfluorocarbon group.

Abstract: The invention relates to an in vitro method for identifying microRNAs or the target mRNAs thereof, the expression of which during the infection of cells by a virus using a cell receptor and at least one cell co-receptor for entering the cell, is specifically modified on the basis of the cell co-receptor used by the virus for its entering the cells, comprising: i) determining the microRNA expression levels in a test cell expressing a receptor, a first co-receptor and at least one other co-receptor, after infection by a first virus using the first co-receptor and by at least one other virus using another co-receptor, respectively; ii) identifying the microRNAs, the expression level of which is modulated during the infection by each of the viruses in relation to the expression level in the uninfected cells; iii) comparing the thus-identified microRNAs; iv) selecting the microRNAs, the modification of the expression level of which is specific to the use of a co-receptor; v) optionally identifying the target mR

Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.

Abstract: A method for the diagnosis and/or prognosis of inflammatory states, and the use of at least one soluble receptor-binding (RBD), for the identification and quantification of the expression of membrane receptors present on the surface of target granulocytes, said identification and quantification taking place at a given time or during a given time interval, and allowing the diagnosis and/or prognosis of inflammatory states in a mammal.

Abstract: The use of metal-accumulating plants for implementing chemical reactions.

Abstract: The present invention relates to a method for preparing a silica grafted with an organosilicon compound, to a grafted silica obtained according to said method and to the use thereof in compositions of silicone crosslinkable into an elastomer.

Abstract: The invention concerns a non-volatile memory element comprising: first and second transistors (106, 108) forming an inverter (104) coupled between a first storage node (112) and an output (110) of the memory element; a third transistor (116) coupled between the first storage node (112) and a first supply voltage (GND, VDD) and comprising a control terminal coupled to said output; a first resistance switching element (102) coupled in series with said third transistor and programmed to have one of first and second resistances (Rmin, Rmax) representing a non-volatile data bit; a fourth transistor (118) coupled between said storage node (112) a second supply voltage (VDD, GND); and control circuitry (130) adapted to activate said third transistor at the start of a transfer phase of said non-volatile data bit to said storage node, and to control said fourth transistor to couple said storage node to said second supply voltage during said transfer phase.

Abstract: The present invention concerns a funtionalisable polysilylated organosilane precursors with formula (I): in which: Z1 represents a moiety with formula (a) and Z2 represents a moiety with formula (b) Z1 and Z2 simultaneously represent a moiety chosen from the moieties R7R8Si(OH), R9Si(OH)2, Si(OH)3, R7R8SiO1/2, R9SiO or Si03/2; U represents a moiety chosen from the moieties with formulas (U1), (U2), (U3), (U4), (U5), (U6), (U7), (U8).

Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.

Abstract: The invention relates to a method for functionalizing natural fatty substances: According to said method, plant oils including at least two unsaturations and the derivatives thereof, fatty acids including at least one unsaturated compound and the derivatives thereof, and mixtures of same, are reacted with a thiol derivative of formula (I), at a temperature of between 0° C. and the temperature of total degradation of the natural fatty substance and in the presence of a thermal initiator compound or a redox initiator, or by UV radiation, or by UV radiation and in the presence of a photoinitiator. The invention also relates to the resulting functionalized fatty substances and to the use thereof for the preparation of polymers. The invention further relates to a method for preparing polymers from at least one functionalized fatty substance obtained by said functionalization method.

Abstract: A method of preventing, inhibiting, or treating cancer that includes contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.

Abstract: The present invention relates to compound (I) for use as an agent for preventing, inhibiting or treating AIDS, wherein X is CR0 or N; R0, R1, R2, R3, R4, R7 and R8 independently represent a hydrogen atom, a halogen atom or a group chosen among a (C1-C5)alkyl group, a (C3-C6)cycloalkyl group, a (C1-C5)fluoroalkyl group, a (C1-C5)alkoxy group, a (C1-C5)fluoroalkoxy group, a —CN group, a —COORa group, a —NO2 group, a —NRaRb group, a —NRa—SO2—NRaRb group, a —NRa—SO2—Ra group, a —NRa—C(?O)—Ra group, a —NRa—C(?O)—NRaRb group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group, a —O—P(?O)—(ORc)(ORd) group, a —O—CH2—COORc group and can further be a group chosen among: R5 represents a hydrogen atom, a (C1-C5)alkyl group or a (C3-C6)cycloalkyl group; R10 is a hydrogen atom or a chlorine atom, and R11 is a hydrogen atom or a (C1-C4)alkyl group or anyone of its pharmaceutically acceptable salts.